The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
Open accessAbstract
PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly assigned to PROSTVAC (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL v 50 ng/mL or more) and lactate dehydrogenase (less than 200 v 200 U/L or more). Primary end point was OS. Secondary end points were patients alive without events (AWE)—namely, radiographic progression, pain progression, chemotherapy initiation, or death—at 6 months and safety. The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus Arm P. Three interim analyses were planned. RESULTS: At the third interim analysis, criteria for futility were met and the trial was stopped early. Neither active treatment had an effect on median OS (Arm V, 34.4 months; hazard ratio, 1.01; 95% CI, 0.84 to 1.20; P = .47; Arm VG, 33.2 months; hazard ratio, 1.02; 95% CI, 0.86 to 1.22; P = .59; Arm P, 34.3 months). Likewise, AWE at 6 months was similar (Arm V, 29.4%; odds ratio, 0.96; 95% CI, 0.71 to 1.29; Arm VG, 28.0%; odds ratio, 0.89; 95% CI, 0.66 to 1.20; placebo, 30.3%). Adverse events were similar for the treatment and placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% to 24%). Arrhythmias were the most common cardiac-related events (1.4% to 3.5%). There were no reports of either myocarditis or pericarditis. Serious treatment-related events occurred in less than 1% of all patients. CONCLUSION: Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 2×
“7 months).(10) Finally, docetaxel was the only life-prolonging treatment available during our phase II study.”
BackgroundSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“Other treatment modalities for mCRPC that have demonstrated overall survival (OS) benefits include chemotherapy (docetaxel and cabazitaxel),(7-9) immunotherapy (sipuleucel-T),(10) and targeted a-therapy (radium-223).(11) PROSTVAC is an active immunotherapy vaccine that contains prostate-specific antigen (PSA) as the t…”
BackgroundSelf-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationFizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citationBerthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Self-citationFilipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
by, P., Bower, W. A., Hendricks, K., Pillai, S., Guarnizo, J., & Meaney-Delman, D. (2015) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6404a1 · Cited by 585
Serafini, P., Carbley, R., Noonan, K. A., Tan, G., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 523
Disis, M., Bernhard, H., Shiota, F., Hand, S., Gralow, Jr., Huseby, E., Gillis, S., & Cheever, M. (1996) · Blood · doi:10.1182/blood.v88.1.202.202 · Cited by 329
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Self-citationStein, W. D., Gulley, J. L., Schlom, J., Madan, R. A., Dahut, W., Figg, W. D., Ning, Y.-M., Arlen, P. M., Price, D., Bates, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1762 · Cited by 247
Self-citationBasch, E., Loblaw, D. A., Oliver, T. K., Carducci, M., Chen, R. C., Frame, J. N., Garrels, K., Hotte, S., Kattan, M. W., Raghavan, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8404 · Cited by 223
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., & Gulley, J. L. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902997928 · Cited by 219
Self-citationUS Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.8359 · Cited by 215
DiPaola, R., Plante, M., Kaufman, H., Petrylak, D., Israeli, R., Lattime, E., Manson, K., & Schuetz, T. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-1 · Cited by 191
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese-Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171
Myopericarditis following Smallpox Vaccination
Arness, M. K. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh269 · Cited by 149
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Gulley, J. L., Madan, R. A., Tsang, K. Y., Jochéms, C., Marté, J. L., Farsaci, B., Tucker, J. A., Hodge, J. W., Liewehr, D. J., Steinberg, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0108 · Cited by 141
Self-citationSynergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach, D. W., Barrientos, J. C., Schlom, J., & Hodge, J. W. (2001) · PubMed · Cited by 132
Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
Arlen, P. M., Skarupa, L., Pazdur, M. P., Seetharam, M., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., Poole, D. J., Litzinger, M. T., Steinberg, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.117 · Cited by 125
Self-citationKass, E. S., Panicali, D., Mazzara, G. P., Schlom, J., & Greiner, J. W. (2001) · PubMed · Cited by 125
Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function
Ribechini, E., Hutchinson, J. A., Hergovits, S., Heuer, M., Lucas, J., Schleicher, U., Garrote, A.-L. J., Potter, S. J., Riquelme, P., Brackmann, H., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006858 · Cited by 102
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91
Morgan, J., Roper, M. H., Sperling, L. S., Schieber, R. A., Heffelfinger, J. D., Casey, C., Miller, J. W., Santibanez, S. S., Herwaldt, B. L., Hightower, P., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/524747 · Cited by 78
Virgo, K. S., Basch, E., Loblaw, D. A., Oliver, T. K., Rumble, R. B., Carducci, M. A., Nordquist, L. T., Taplin, M., Winquist, E., & Singer, E. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8030 · Cited by 68
Kantoff, P. W., Gulley, J. L., & Navarro, C. P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7748 · Cited by 67
Self-citationElucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
Mandl, S. J., Rountree, R. B., Cruz, T. D., Foy, S. P., Cote, J. J., Gordon, E. J., Trent, E., Delcayre, A. X., & Franzusoff, A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/preaccept-3619132851279195 · Cited by 19
Cited by
Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Cai, M., Song, X.-L., Li, X.-A., Chen, M., Guo, J., Yang, D.-H., Chen, Z., & Zhao, S.-C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 262
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Metadata
- Authors
- Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., & Kantoff, P. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-05-01
- Volume
- 37
- Issue
- 13
- Pages
- 1051-1061
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2915177933
- Cited by
- 285
- References
- 33
- FWCI
- 23.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.